Market News AIOpen the app

Alzamend Neuro ended a clinical trial for bipolar disorder because it had trouble finding patients.

TrialRead the original at SEC EDGAR
Bad for ALZN

The FDA questioned whether ALZN’s current studies could show that the drug works, and MGH ended the bipolar study. The completed healthy-subject study and planned FDA meeting offer possible next steps, but no revised plan has FDA approval.

ALZN · Alzamend Neuro, Inc.

AI read · Bad for ALZN

The AI's read

ALZN no longer has an active bipolar study, and the FDA questioned whether its current studies could show that the drug works. The completed healthy-subject study and expected results in December offer useful information, but they do not settle the FDA’s concern. ALZN plans to ask the FDA about a revised plan, possibly a Phase III bipolar study. The FDA’s response is not expected until the end of the second quarter of 2027, so the next testing steps remain uncertain.

Get alerts for ALZN

Follow Alzamend Neuro, Inc. (ALZN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ALZN
Free on the App Store and Google Play, or on the web.